Sterile endophthalmitis after intravitreal injections

Mediators of Inflammation

Volumn 2012, Issue , 2012, Pages

  Marticorena, Joaquín ^a   Romano, Vito ^b   Gómez Ulla, Francisco ^a,c  

^a Instituto Oftalmológico Gómez Ulla   (Spain)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; METHOTREXATE; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; MONOCLONAL ANTIBODY; TRIAMCINOLONE;

DISEASE COURSE; DISEASE SEVERITY; ENDOPHTHALMITIS; EYE INFLAMMATION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PSEUDOENDOPHTHALMITIS; PSEUDOHYPOPYON; REVIEW; STERILE ENDOPHTHALMITIS; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY; IMMUNOLOGY; INFLAMMATION; INTRAVITREAL DRUG ADMINISTRATION; OFF LABEL DRUG USE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ENDOPHTHALMITIS; HUMANS; INFLAMMATION; INTRAVITREAL INJECTIONS; OFF-LABEL USE; TRIAMCINOLONE;

EID: 84866133085     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2012/928123     Document Type: Review

References (59)

1. Rycroft B. W., Penicillin and the control of deep intra-ocular infection. British Journal of Ophthalmology 1945 29 2 57 87
2. Endophthalmitis Vitrectomy Study Group, Results of the endophthalmitis vitrectomy study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis, Endophthalmitis Vitrectomy Study Group. Archives of Ophthalmology 1995 113 12 1479 1496 2-s2.0-0028839594
3. Sutter F. K. P., Gillies M. C., Pseudo-endophthalmitis after intravitreal injection of triamcinolone. British Journal of Ophthalmology 2003 87 8 972 974 2-s2.0-0041705920 10.1136/bjo.87.8.972 (Pubitemid 36936293)
4. Roth D. B., Chieh J., Spirn M. J., Green S. N., Yarian D. L., Chaudhry N. A., Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Archives of Ophthalmology 2003 121 9 1279 1282 2-s2.0-0141499061 10.1001/archopht.121.9.1279 (Pubitemid 37128405)
5. Nelson M. L., Tennant M. T. S., Sivalingam A., Regillo C. D., Belmont J. B., Martidis A., Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003 23 5 686 691 2-s2.0-0142244629 10.1097/00006982-200310000-00014 (Pubitemid 37315056)
6. Özkiriş A., Erkiliç K., Complications of intravitreal injection of triamcinolone acetonide. Canadian Journal of Ophthalmology 2005 40 1 63 68 2-s2.0-16344389598 (Pubitemid 40470519)
7. Moshfeghi D. M., Kaiser P. K., Bakri S. J., Kaiser R. S., Maturi R. K., Sears J. E., Scott I. U., Belmont J., Beer P. M., Quiroz-Mercado H., Mieler W. F., Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surgery Lasers and Imaging 2005 36 1 24 29 2-s2.0-19944432858 (Pubitemid 40128598)
8. Wang L. C., Yang C. M., Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide. Ocular Immunology and Inflammation 2005 13 4 295 300 2-s2.0-26944488400 10.1080/09273940590951007 (Pubitemid 41702772)
9. Jonas J. B., Kreissig I., Spandau U. H., Harder B., Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. American Journal of Ophthalmology 2006 141 3 579 580 2-s2.0-33144475205 10.1016/j.ajo.2005.10.007 (Pubitemid 43265975)
10. Marticorena J., Gomez-Ulla F., Romano M. R., Luna I., Repeated pseudoendophthalmitis after combined photodynamic therapy and intravitreal triamcinolone. Graefe's Archive for Clinical and Experimental Ophthalmology 2007 245 9 1403 1404 2-s2.0-34548008862 10.1007/s00417-007-0592-7 (Pubitemid 47278681)
11. Carrero J. L., Barcia M. G., Flores I. P., Sterile endophthalmitis after benzyl alcohol-filtered triamcinolone acetonide injection. Archives of Ophthalmology 2008 126 1 142 143 2-s2.0-38349073483 10.1001/archophthalmol.2007. 20
12. Jonisch J., Lai J. C., Deramo V. A., Flug A. J., Fastenberg D. M., Increased incidence of sterile endophthalmitis following intravitreal preserved triamcinolone acetonide. British Journal of Ophthalmology 2008 92 8 1051 1054 2-s2.0-49049092808 10.1136/bjo.2007.136069
13. Kai W., Yanrong J., Xiaoxin L., Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Graefe's Archive for Clinical and Experimental Ophthalmology 2006 244 9 1152 1159 2-s2.0-33747640491 10.1007/s00417-005-0251-9 (Pubitemid 44269594)
14. Yeung C. K., Chan K. P., Chiang S. W. Y., Pang C. P., Lam D. S. C., The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Investigative Ophthalmology and Visual Science 2003 44 12 5293 5300 2-s2.0-0344851534 10.1167/iovs.03-0490 (Pubitemid 37475401)
15. Yeung C. K., Chan K. P., Chan C. K. M., Pang C. P., Lam D. S. C., Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Japanese Journal of Ophthalmology 2004 48 3 236 242 2-s2.0-2542467968 10.1007/s10384-003-0053-8 (Pubitemid 38691431)
16. Morrison V. L., Koh H. J., Cheng L., Bessho K., Davidson M. C., Freeman W. R., Intravitreal toxicity of the Kenalog vehicle (benzyl alcohol) in rabbits. Retina 2006 26 3 339 344 2-s2.0-33646448054 10.1097/00006982-200603000-00014 (Pubitemid 44318189)
17. Yu S. Y., Damico F. M., Viola F., D'Amico D. J., Young L. H., Retinal toxicity of intravitreal triamcinolone acetonide: a morphological study. Retina 2006 26 5 531 536 2-s2.0-33745771165 10.1097/00006982-200605000-00006 (Pubitemid 44620394)
18. McCuen B. W., Bessler M., Tano Y., The lack of toxicity of intravitreally administered triamcinolone acetonide. American Journal of Ophthalmology 1981 91 6 785 788 2-s2.0-0019499435 (Pubitemid 11078533)
19. Hida T., Chandler D., Arena J. E., Machemer R., Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. American Journal of Ophthalmology 1986 101 2 190 195 2-s2.0-0022623725 (Pubitemid 16136575)
20. Dierks D., Lei B., Zhang K., Hainsworth D. P., Electroretinographic effects of an intravitreal injection of triamcinolone in rabbit retina. Archives of Ophthalmology 2005 123 11 1563 1569 2-s2.0-27744535215 10.1001/archopht.123. 11.1563 (Pubitemid 41626693)
21. Beaudouin E., Kanny G., Gueant J. L., Moneret-Vautrin D. A., Anaphylaxis to carboxymethylcellulose induced by injectable corticosteroids. Allergie et Immunologie 1992 24 9 333 335 2-s2.0-0026950963 (Pubitemid 23014686)
22. Curry E. J., Warshaw E. M., Benzyl alcohol allergy: importance of patch testing with personal products. Dermatitis 2005 16 4 203 208 2-s2.0-30144433681 (Pubitemid 43053765)
23. Montoro J., Valero A., Elices A., Rubira N., Serra-Baldrich E., Amat P., Malet A., Anaphylactic shock after intra-articular injection of carboxymethylcellulose. Allergologia et Immunopathologia 2000 28 6 332 333 2-s2.0-0034500356 (Pubitemid 32066210)
24. Moshfeghi A. A., Scott I. U., Flynn H. W., Puliafito C. A., Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. American Journal of Ophthalmology 2004 138 3 489 492 2-s2.0-4444235582 10.1016/j.ajo.2004.03.025 (Pubitemid 39208586)
25. Jager R. D., Aiello L. P., Patel S. C., Cunningham E. T., Risks of intravitreous injection: a comprehensive review. Retina 2004 24 5 676 698 2-s2.0-6344282189 10.1097/00006982-200410000-00002 (Pubitemid 39391758)
26. Chen S. D. M., Lochhead J., McDonald B., Patel C. K., Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema. British Journal of Ophthalmology 2004 88 6 843 844 2-s2.0-2642512355 10.1136/bjo.2003.033589 (Pubitemid 38725609)
27. Amato J. E., Lee D. H., Santos B. A., Akduman L., Steroid hypopyon following intravitreal triamcinolone acetonide injection in a pseudophakic patient. Ocular Immunology and Inflammation 2005 13 2-3 245 247 2-s2.0-25144465148 10.1080/09273940590928562 (Pubitemid 41711298)
28. Garay-Aramburu G., Bilbao-Urtiaga A., Cuesta-García M., Larrauri-Arana A., A case of triamcinolone-induced pseudo-endophthalmitis after vitrectomy. Archivos de la Sociedad Española de Oftalmología. 2005 80 10 615 617 2-s2.0-33645841368
29. Jonas J. B., Hayler J. K., Panda-Jonas S., Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. British Journal of Ophthalmology 2000 84 9 1064 1067 2-s2.0-0033825585 10.1136/bjo.84.9.1064
30. Sharma M. C., Lai W. W., Shapiro M. J., Pseudohypopyon following intravitreal triamcinolone acetonide injection. Cornea 2004 23 4 398 399 2-s2.0-2142653620 10.1097/00003226-200405000-00016 (Pubitemid 38544059)
31. Blanco Marchite C., Fagúndez A., Buznego L., López-Moya J., Leak of intravitreal triamcinolone to the anterior chamber. Archivos de la Sociedad Espanola de Oftalmologia 2007 82 12 781 783 2-s2.0-38849150298
32. Chiu Y. T., Tsai Y. Y., Lin J. M., Noninfectious hypopion after intravitreal triamcinolone acetonide injection for central retinal vein occlusion: a case report. Kaohsiung Journal of Medical Sciences 2005 21 10 466 469 2-s2.0-27844553808
33. Ruiz-Moreno J. M., Montero J. A., Artola A., Barile S., Anterior chamber transit of triamcinolone after intravitreal injection. Archives of Ophthalmology 2005 123 1 129 130 2-s2.0-12144279611 (Pubitemid 40105453)
34. Jonas J. B., Hayler J. K., Söfker A., Panda-Jonas S., Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. American Journal of Ophthalmology 2001 131 4 468 471 2-s2.0-0035056573 10.1016/S0002-9394(00)00882-5 (Pubitemid 32273433)
35. Rosenfeld P. J., Fung A. E., Puliafito C. A., Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surgery Lasers and Imaging 2005 36 4 336 339 2-s2.0-23044440795 (Pubitemid 41073113)
36. Rosenfeld P. J., Moshfeghi A. A., Puliafito C. A., Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surgery Lasers and Imaging 2005 36 4 331 335 2-s2.0-23044505200 (Pubitemid 41073112)
37. Wu L., Martínez-Castellanos M. A., Quiroz-Mercado H., Arevalo J. F., Berrocal M. H., Farah M. E., Maia M., Roca J. A., Rodriguez F. J., Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the pan-american collaborative retina study group (PACORES). Graefe's Archive for Clinical and Experimental Ophthalmology 2008 246 1 81 87 2-s2.0-36448993366 10.1007/s00417-007-0660-z (Pubitemid 350167096)
38. Fintak D. R., Shah G. K., Blinder K. J., Regillo C. D., Pollack J., Heier J. S., Hollands H., Sharma S., Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008 28 10 1395 1399 2-s2.0-58949083350 10.1097/IAE.0b013e3181884fd2
39. Artunay O., Yuzbasioglu E., Rasier R., Sengül A., Bahcecioglu H., Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye 2009 23 12 2187 2193 2-s2.0-68949120403 10.1038/eye.2009.7
40. Chong D. Y., Anand R., Williams P. D., Qureshi J. A., Callanan D. G., Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina 2010 30 9 1432 1440 2-s2.0-78049233669 10.1097/IAE.0b013e3181dc04da
41. Fung A. E., Rosenfeld P. J., Reichel E., The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. British Journal of Ophthalmology 2006 90 11 1344 1349 2-s2.0-33750296920 10.1136/bjo.2006.099598 (Pubitemid 44702055)
42. Georgopoulos M., Polak K., Prager F., Prünte C., Schmidt-Erfurth U., Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). British Journal of Ophthalmology 2009 93 4 457 462 2-s2.0-64849085452 10.1136/bjo.2008.138479
43. Wickremasinghe S. S., Michalova K., Gilhotra J., Guymer R. H., Harper C. A., Wong T. Y., Qureshi S., Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008 115 11 1911.e1 1915.e1 2-s2.0-54949136462 10.1016/j.ophtha.2008.05.007
44. Yamashiro K., Tsujikawa A., Miyamoto K., Oh H., Otani A., Tamuara H., Ooto S., Sasahara M., Iwama D., Yoshimura N., Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 2010 30 3 485 490 2-s2.0-77949369713 10.1097/IAE.0b013e3181bd2d51
45. van der Reis M. I., la Heij E. C., de Jong-Hesse Y., Ringens P. J., Hendrikse F., Schouten J., A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011 31 8 1449 1469 2-s2.0-79961108358 10.1097/IAE.0b013e3182278ab4
46. Bakri S. J., Larson T. A., Edwards A. O., Intraocular inflammation following intravitreal injection of bevacizumab. Graefe's Archive for Clinical and Experimental Ophthalmology 2008 246 5 779 781 2-s2.0-42049115622 10.1007/s00417-007-0754-7
47. Kay C. N., Tarantola R. M., Gehrs K. M., Uveitis following intravitreal bevacizumab: a non-infectious cluster. Ophthalmic Surgery, Lasers and Imaging 2011 42 4 292 296
48. Sato T., Emi K., Ikeda T., Bando H., Sato S., Morita S. I., Oyagi T., Sawada K., Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology 2010 117 3 512.e2 516.e2 2-s2.0-77049116746 10.1016/j.ophtha.2009.07.041
49. Yenerel N. M., Dinc U. A., Gorgun E., A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection. Journal of Ocular Pharmacology and Therapeutics 2008 24 3 362 363 2-s2.0-44349166204 10.1089/jop.2007.0126 (Pubitemid 351733229)
50. Remick D. G., Kunkel R. G., Larrick J. W., Kunkel S. L., Acute in vivo effects of human recombinant tumor necrosis factor. Laboratory Investigation 1987 56 6 583 590 2-s2.0-0023192336 (Pubitemid 17095929)
51. Genetech, Avastin (Bevacizumab): Highlights of Prescribing Information 2011 San Francisco, Calif, USA Genetech
52. Hochuli E., Interferon immunogenicity: technical evaluation of interferon- α 2a. Journal of Interferon and Cytokine Research 1997 17 supplement 1 S15 S21 2-s2.0-0030803840
53. Koren E., Zuckerman L. A., Mire-Sluis A. R., Immune responses to therapeutic proteins in humansclinical significance, assessment and prediction. Current Pharmaceutical Biotechnology 2002 3 4 349 360 2-s2.0-0036890997 10.2174/1389201023378175 (Pubitemid 35364009)
54. The CATT Research Group, Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2011 364 20 1897 1908 2-s2.0-79956218863 10.1056/NEJMoa1102673
55. Fauser S., Schroeder S., Caramoy A., Kirchhof B., Lappas A., Intraocular inflammation after intravitreal ranibizumab injections. Acta Ophthalmologica 2011 89 1 e98 e99 2-s2.0-79551552054 10.1111/j.1755-3768.2010.01900.x
56. Sharma S., Johnson D., Abouammoh M., Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Canadian Journal of Ophthalmology 2012 47 3 275 279
57. Smith J. R., Rosenbaum J. T., Wilson D. J., Doolittle N. D., Siegal T., Neuwelt E. A., Pe'er J., Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002 109 9 1709 1716 2-s2.0-0036713850 10.1016/S0161-6420(02)01125-9 (Pubitemid 35012013)
58. Frenkel S., Hendler K., Siegal T., Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. British Journal of Ophthalmology 2008 92 3 383 388 2-s2.0-40549089547 10.1136/bjo.2007.127928 (Pubitemid 351363536)
59. Holland S. P., Morck D. W., Lee T. L., Update on toxic anterior segment syndrome. Current Opinion in Ophthalmology 2007 18 1 4 8 2-s2.0-33845654254 10.1097/ICU.0b013e3280117d0c (Pubitemid 44949818)